UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 153

Sortiert nach

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

European journal of cancer (1990), 2009-01, Vol.45 (2), p.228-247

2009

Volltextzugriff (PDF)

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

JNCI : Journal of the National Cancer Institute, 1997-08, Vol.89 (15), p.1138-1147

1997

Volltextzugriff (PDF)

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

British journal of cancer, 2001-05, Vol.84 (10), p.1424-1431

2001

Volltextzugriff (PDF)

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

Journal of clinical oncology, 2001-01, Vol.19 (1), p.265-272

2001

Volltextzugriff (PDF)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2319-2333

2001

Volltextzugriff (PDF)

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Journal of clinical oncology, 1998-09, Vol.16 (9), p.2986-2999

1998

Volltextzugriff (PDF)

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

JNCI : Journal of the National Cancer Institute, 2000-02, Vol.92 (3), p.205-216

2000

Volltextzugriff (PDF)

Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop

Gynecologic oncology, 2007-11, Vol.107 (2), p.173-176

2007

Volltextzugriff (PDF)

Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

Annals of oncology, 2001-08, Vol.12 (8), p.1067-1073

2001

Volltextzugriff (PDF)

Clinical toxicities encountered with paclitaxel (TAXOL®)

Seminars in oncology, 1993-08, Vol.20 (4), p.1-15

1993

Volltextzugriff (PDF)

Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition

Clinical cancer research, 2001-06, Vol.7 (6), p.1758-1764

2001

Volltextzugriff (PDF)

Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2413-2421

2001

Volltextzugriff (PDF)

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996

Annals of oncology, 1996-08, Vol.7 (6), p.567

Arbuck, S G

1996

Volltextzugriff (PDF)

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Journal of clinical oncology, 1993-12, Vol.11 (12), p.2405-2410

1993

Volltextzugriff (PDF)

Clinical pharmacology of UCN-01 : initial observations and comparison to preclinical models

Cancer chemotherapy and pharmacology, 1998-08, Vol.42 (S1), p.S54-S59

1998

Volltextzugriff (PDF)

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

Journal of clinical oncology, 1995-08, Vol.13 (8), p.2056-2065

1995

Volltextzugriff (PDF)

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

Journal of clinical oncology, 1991-12, Vol.9 (12), p.2128-2133

1991

Volltextzugriff (PDF)

Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target

Pharmacology & therapeutics (Oxford), 1999-05, Vol.82 (2), p.285-292

1999

Volltextzugriff (PDF)

Taxol: the first of the taxanes, an important new class of antitumor agents

Seminars in oncology, 1992-12, Vol.19 (6), p.646-662

1992

Volltextzugriff (PDF)

Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer

Cancer, 1989-03, Vol.63 (S6), p.1036-1044

Arbuck, Susan G.

1989

Volltextzugriff (PDF)

An overview of topoisomerase I-targeting agents

Seminars in hematology, 1998-07, Vol.35 (3 Suppl 4), p.3

1998

Volltextzugriff (PDF)

Paclitaxel: what schedule? What dose?

Journal of clinical oncology, 1994-02, Vol.12 (2), p.233-236

Arbuck, S G

1994

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

Journal of clinical oncology, 1997-04, Vol.15 (4), p.1492-1501

1997

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients

Journal of clinical oncology, 2000-02, Vol.18 (3), p.659-667

2000

Volltextzugriff (PDF)

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1236-1244

1996

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Englisch
(153)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Humans
(113)
Science & Technology
(86)
Life Sciences & Biomedicine
(85)
Oncology
(71)
Female
(70)
Biological And Medical Sciences
(69)
Medical Sciences
(68)
Pharmacology. Drug Treatments
(65)
Antineoplastic Agents
(61)
Middle Aged
(54)
Adult
(53)
Aged
(48)
Chemotherapy
(48)
Male
(47)
Neoplasms - Drug Therapy
(38)
Antineoplastic Agents - Therapeutic Use
(24)
Clinical Trials As Topic
(24)
Drug Administration Schedule
(23)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Infusions, Intravenous
(21)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop

Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

Clinical toxicities encountered with paclitaxel (TAXOL®)

Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition

Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Clinical pharmacology of UCN-01 : initial observations and comparison to preclinical models

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target

Taxol: the first of the taxanes, an important new class of antitumor agents

Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer

An overview of topoisomerase I-targeting agents

Paclitaxel: what schedule? What dose?

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

Suchergebnisse filtern